# Efficacy and Tolerability of HAT1 in Patients With Moderate to Severe Atopic Dermatitis

> **NCT03059693** · PHASE1,PHASE2 · COMPLETED · sponsor: **Haus Bioceuticals** · enrollment: 48 (actual)

## Conditions studied

- Dermatitis, Atopic

## Interventions

- **DRUG:** HAT1 topical cream
- **DRUG:** Vehicle cream

## Key facts

- **NCT ID:** NCT03059693
- **Lead sponsor:** Haus Bioceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-29
- **Primary completion:** 2016-06-13
- **Final completion:** 2016-07-24
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03059693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03059693, "Efficacy and Tolerability of HAT1 in Patients With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03059693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*